AA
CLVS

Apriem Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

Apriem Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-200
Closed -$13K – 588
2017
Q1 		$13K Sell
200
-200
-50% -$12.2K ﹤0.01% 397
2016
Q4 		$18K Hold
400
– – 0.01% 373
2016
Q3 		$14K Hold
400
– – ﹤0.01% 373
2016
Q2 		$5K Hold
400
– – ﹤0.01% 468
2016
Q1 		$8K Hold
400
– – ﹤0.01% 397
2015
Q4 		$14K Buy
+400
New +$25.8K 0.01% 340

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Apriem Advisors's CLVS Position: Q2 2017 in Review

Apriem Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q2 2017, closing a stake of 200 shares — an estimated $13K sold.

Apriem Advisors first reported a position in CLVS in Q4 2015 and held it in 6 quarters. The position peaked at $18K in Q4 2016. 271 funds tracked by Wall St. Rank hold CLVS as of Q2 2017.

  • Apriem Advisors reported no remaining Clovis Oncology, Inc. position as of Q2 2017 after selling out during the quarter.
  • Apriem Advisors sold 200 Clovis Oncology, Inc. shares in Q2 2017, an estimated $13K.
  • Apriem Advisors first reported a position in Clovis Oncology, Inc. in Q4 2015 and held it in 6 quarters.
  • Apriem Advisors's Clovis Oncology, Inc. position peaked at $18K in Q4 2016.
  • 271 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2017.

Based on Apriem Advisors's 13F filing for Q2 2017, filed 4 Aug 2017.